Cover Image
市場調查報告書

呼吸系統醫藥品的全球市場:2016∼2020年

Global Resipiratory Drugs Market 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 357731
出版日期 內容資訊 英文 120 Pages
訂單完成後即時交付
價格
Back to Top
呼吸系統醫藥品的全球市場:2016∼2020年 Global Resipiratory Drugs Market 2016-2020
出版日期: 2016年05月04日 內容資訊: 英文 120 Pages
簡介

氣喘、COPD、過敏性鼻炎、肺高血壓、囊狀纖維化症、IPF等主要呼吸器官疾病中,氣喘與COPD的全球罹患率特別高。環境污染、生活習慣的變化等是主要原因,輕度到中度的治療方法有使用經鼻皮質類固醇、抗組織胺、免疫抑制劑、支氣管擴張劑、白三烯拮抗劑等。全球呼吸系統醫藥品市場在2016∼2020年這段期間預測將以年複合成長率6.48%擴大。

本報告提供全球呼吸系統醫藥品市場現狀與到2020年前的成長預測,彙整市場趨勢與課題,各地區趨勢,主要供應商簡介等資料。

第1章 摘要整理

第2章 本報告的範圍

第3章 市場調查方法

第4章 簡介

第5章 概要:呼吸疾病

  • 氣喘
  • COPD
  • 過敏性鼻炎
  • 肺高血壓
  • 囊狀纖維化症
  • IPF
  • 美國FDA核准的呼吸系統醫藥品

第6章 開發平台分析

第7章 市場情況

  • 波特的五力分析

第8章 醫藥品各級市場區隔

第9章 不同疾病市場區隔

第10章 各地區市場區隔

  • 各地區市場
  • 南北美洲
  • 歐洲·中東·非洲
  • 亞太地區

第11章 推動市場的要素

  • 有潛力的後期開發平台分子
  • 呼吸疾病罹患率上升
  • 老年人的增加
  • 抽煙率高
  • 環境污染的擴大

第12章 促進要素的影響

第13章 市場課題

  • 複數專利失效
  • 氣喘和IPF的病因不明
  • 低診斷率
  • 藥物的副作用
  • CAM偏好的警告

第14章 促進要素與課題的影響

第15章 市場趨勢

第16章 供應商環境

  • 競爭模式
  • 市場佔有率分析:2015年
  • AstraZeneca
  • Boehringer Ingelheim
  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • Merck
  • Novartis
  • 其他值得注意的供應商

第17章 附錄

第18章 關於Technavio

圖表

目錄
Product Code: IRTNTR8439

About Respiratory Ailments

Asthma, COPD, allergic rhinitis, pulmonary hypertension, cystic fibrosis, and IPF are some of the major respiratory diseases. Among these, asthma and COPD are the most prevalent worldwide. Environmental pollution, changing lifestyles, and hereditary factors are some of the common causes of respiratory diseases. Intranasal corticosteroids, antihistamines, immunosuppressants, bronchodilators, and leukotriene antagonists are the respiratory medicines that are commonly used for the treatment of mild-to-moderate respiratory diseases. However, the choice of drug depends on the type and severity of the disease.

Technavio's analysts forecast the global respiratory drugs market to grow at a CAGR of 6.48% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global respiratory drugs market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of prescription and over-the-counter (OTC) drugs used to treat respiratory diseases.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Respiratory Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • AstraZeneca
  • Boehringer Ingelheim
  • F.Hoffman La-Roche
  • GlaxoSmithKline
  • Merck
  • Novartis

Other Prominent Vendors

  • Abbott
  • Actavis
  • Afferent Pharmaceuticals
  • Alere
  • Almirall
  • Amgen
  • AptarGroup
  • Astellas
  • Aurobindo
  • Axis Shield
  • Baxter
  • Bayer
  • Biogen
  • Biotest
  • Bristol-Myers Squibb
  • Chiesi Farmaceutici
  • Cipla
  • Cytos
  • Dainippon Sumitomo
  • Dr. Reddy's Laboratories
  • FibroGen
  • Gilead Sciences
  • Glenmark
  • GNI Group Ltd
  • Horizon Pharma
  • ImmuneWorks
  • MediciNova
  • MedImmune
  • Mylan
  • Ono Pharmaceutical
  • Orchid Chemicals and Pharmaceuticals
  • Perrigo
  • Pfizer
  • Promedior
  • Prometheus
  • ProMetic Life Sciences
  • Ranbaxy
  • Rottapharm Madaus
  • Sanofi
  • Shionogi
  • Siemens Healthcare Diagnostics
  • Skyepharma
  • Sosei
  • Sunovion
  • Takeda Pharmaceutical
  • Teva
  • Theravance
  • United Therapeutics
  • Vectura
  • Vertex
  • Zai Lab

Market driver

  • Rise in prevalence of respiratory diseases
  • For a full, detailed list, view our report

Market challenge

  • Unknown etiology of asthma and idiopathic pulmonary fibrosis
  • For a full, detailed list, view our report

Market trend

  • Use of biologics
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Overview: Respiratory diseases

  • Asthma
  • COPD
  • Allergic rhinitis
  • Pulmonary hypertension
  • Cystic fibrosis
  • IPF
  • US FDA-approved respiratory drugs

PART 06: Pipeline analysis

  • Information on some pipeline candidates

PART 07: Market landscape

  • Five forces analysis

PART 08: Market segmentation by class of drugs

  • Bronchodilators
  • Leukotriene antagonists
  • Mast cell stabilizers
  • Immunosuppressants
  • Combination of LABA/ICS
  • Tyrosine kinase inhibitors
  • Antifibrotic agents
  • Antihistamines
  • Endothelin (ET) receptor antagonist
  • Prostacyclin analogs
  • Phosphodiesterase inhibitors
  • Soluble guanylate cyclase (sGC) stimulators

PART 09: Market segmentation by disease

  • Global asthma drugs market
  • Global COPD drugs market
  • Global allergic rhinitis drugs market
  • Global pulmonary hypertension drugs market
  • Global cystic fibrosis drugs market
  • Global IPF drugs market

PART 10: Geographical segmentation

  • Global respiratory drugs market by geography 2015-2020
  • Respiratory drugs market in Americas
  • Respiratory drugs market in EMEA
  • Respiratory drugs market in APAC

PART 11: Market drivers

  • Promising late-stage pipeline molecules
  • Rise in prevalence of respiratory diseases
  • Increase in older adult population
  • High usage of tobacco
  • Increase in environmental pollution

PART 12: Impact of drivers

PART 13: Market challenges

  • Multiple patent expiries
  • Unknown etiology of asthma and IPF
  • Low diagnosis rates
  • Adverse effects of drugs
  • Increased preference for CAM

PART 14: Impact of drivers and challenges

PART 15: Market trends

  • Increasing awareness about respiratory diseases
  • Patient assistance programs
  • Usage of biologics
  • Self-medication using OTC products
  • Strategic alliances

PART 16: Vendor landscape

  • Competitive scenario
  • Market share analysis 2015
  • AstraZeneca
  • Boehringer Ingelheim
  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • Merck
  • Novartis
  • Other prominent vendors

PART 17: Appendix

  • List of abbreviations

PART 18: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Objectives of asthma management
  • Exhibit 03: COPD: Prevalence in six EU countries
  • Exhibit 04: Management of COPD
  • Exhibit 05: Prevalence rate of allergic rhinitis in China
  • Exhibit 06: Summary of pharmacologic treatments for allergic rhinitis
  • Exhibit 07: Non-pharmacological therapies for allergic rhinitis
  • Exhibit 08: Prevalence of cystic fibrosis by country 2014
  • Exhibit 09: Treatment options for IPF
  • Exhibit 10: Drugs approved by US FDA for respiratory diseases 2000-2015
  • Exhibit 11: Pipeline portfolio of major drug candidates for respiratory diseases
  • Exhibit 12: Global respiratory drugs market 2015-2020 ($ billions)
  • Exhibit 13: Global respiratory drugs market by diseases 2015
  • Exhibit 14: Five forces analysis
  • Exhibit 15: Global asthma drugs market 2015-2020 ($ billions)
  • Exhibit 16: Key drivers and challenges of global asthma drugs market
  • Exhibit 17: Global asthma drugs market by class of drugs 2015
  • Exhibit 18: Global COPD drugs market 2015-2020 ($ billions)
  • Exhibit 19: Key drivers and challenges of global COPD drugs market
  • Exhibit 20: Global COPD drugs market by class of drugs 2015
  • Exhibit 21: Global allergic rhinitis drugs market 2015-2020 ($ billions)
  • Exhibit 22: Key drivers and challenges of global allergic rhinitis drugs market
  • Exhibit 23: Global allergic rhinitis drugs market by class of drugs 2015
  • Exhibit 24: Global pulmonary hypertension drugs market 2015-2020 ($ billions)
  • Exhibit 25: Key drivers and challenges for global pulmonary hypertension drugs market
  • Exhibit 26: Global pulmonary hypertension drugs market by class of drugs 2015
  • Exhibit 27: Global cystic fibrosis drugs market 2015-2020 ($ billions)
  • Exhibit 28: Key drivers and challenges for global cystic fibrosis drugs market
  • Exhibit 29: Global cystic fibrosis drugs market by type of molecule 2015
  • Exhibit 30: Global IPF market 2015-2020 ($ billions)
  • Exhibit 31: Key drivers and challenges for global IPF drugs market
  • Exhibit 32: Global respiratory drugs market: YoY revenue and growth based on respiratory diseases 2015-2020
  • Exhibit 33: Global respiratory drugs market by geography 2015
  • Exhibit 34: Global respiratory drugs market revenue by geography 2015-2020 ($ billions)
  • Exhibit 35: Respiratory drugs market in Americas 2015-2020 ($ billions)
  • Exhibit 36: Respiratory drugs market in EMEA 2015-2020 ($ billions)
  • Exhibit 37: Respiratory drugs market in APAC 2015-2020 ($ billions)
  • Exhibit 38: Global respiratory drugs market; YoY revenue and growth based on geography 2015-2020
  • Exhibit 39: Impact of drivers
  • Exhibit 40: Impact of drivers and challenges
  • Exhibit 41: Drugs that converted from Rx to OTC
  • Exhibit 42: Global respiratory drugs market share analysis 2015
  • Exhibit 43: Top selling respiratory drugs based on their revenue in 2014
  • Exhibit 44: AstraZeneca: Percentage share of products sales by therapy area 2014
  • Exhibit 45: AstraZeneca: YoY growth and revenue of Symbicort 2012-2014 ($ billions)
  • Exhibit 46: AstraZeneca: YoY growth and revenue of Pulmicort 2012-2014 ($ billions)
  • Exhibit 47: AstraZeneca: Key takeaways
  • Exhibit 48: Boehringer Ingelheim: YoY growth and revenue of Spiriva 2012-2014 ($ billions)
  • Exhibit 49: Boehringer Ingelheim: YoY growth and revenue of Combivent 2012-2014 ($ millions)
  • Exhibit 50: Boehringer Ingelheim: Key takeaways
  • Exhibit 51: F. Hoffmann-La Roche: YoY growth and revenue of Xolair in the US 2012-2014 ($ millions)
  • Exhibit 52: F. Hoffmann-La Roche: YoY growth and revenue of Pulmozyme 2012-2014 ($ millions)
  • Exhibit 53: F. Hoffmann-La Roche: Key takeaways
  • Exhibit 54: GlaxoSmithKline: Percentage share of products sales by therapy area 2014
  • Exhibit 55: GlaxoSmithKline: YoY growth and revenue of Seretide/Advair 2012-2014 ($ billions)
  • Exhibit 56: GlaxoSmithKline: YoY growth and revenue of Flixotide/Flovent 2012-2014 ($ billions)
  • Exhibit 57: GlaxoSmithKline: YoY growth and revenue of Ventolin 2012-2014 ($ billions)
  • Exhibit 58: GlaxoSmithKline: YoY growth and revenue of Avamys/Veramyst 2012-2014 ($ millions)
  • Exhibit 59: GlaxoSmithKline: YoY revenue of Avamys/Veramyst 2013 and 2014 ($ millions)
  • Exhibit 60: GlaxoSmithKline: Key takeaways
  • Exhibit 61: Merck: YoY growth and revenue of Nasonex 2012-2014 ($ billions)1
  • Exhibit 62: Merck: YoY growth and revenue of Singulair 2012-2014 ($ billions)2
  • Exhibit 63: Merck: YoY growth and revenue of Clarinex 2012-2014 ($ millions)2
  • Exhibit 64: Merck: Key takeaways4
  • Exhibit 65: Novartis: YoY growth and revenue of Xolair (outside the US) 2012-2014 ($ millions)6
  • Exhibit 66: Novartis: YoY growth and revenue of TOBI 2012-2014 ($ millions)6
  • Exhibit 67: Novartis: YoY growth and revenue of Onbrez Breezhaler 2012-2014 ($ millions)7
  • Exhibit 68: Novartis: YoY growth and revenue of Seebri Breezhaler 2012-2014 ($ millions)7
  • Exhibit 69: Novartis: YoY revenue of Ultibro Breezhaler 2013 and 2014 ($ millions)8
  • Exhibit 70: Novartis: YoY growth and revenue of Foradil Aerolizer sold outside the US 2012-2014 ($ millions)8
  • Exhibit 71: Novartis: Key takeaways9
Back to Top